{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:06:29Z","timestamp":1791511589292,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We report an analysis of the propensity of the antimalarial agent cabamiquine, a\n                    <jats:italic>Plasmodium<\/jats:italic>\n                    -specific eukaryotic elongation factor 2 inhibitor, to select for resistant\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    parasites. Through in vitro studies of laboratory strains and clinical isolates, a humanized mouse model, and volunteer infection studies, we identified resistance-associated mutations at 11 amino acid positions. Of these, six (55%) were present in more than one infection model, indicating translatability across models. Mathematical modelling suggested that resistant mutants were likely pre-existent at the time of drug exposure across studies. Here, we estimated a wide range of frequencies of resistant mutants across the different infection models, much of which can be attributed to stochastic differences resulting from experimental design choices. Structural modelling implicates binding of cabamiquine to a shallow mRNA binding site adjacent to two of the most frequently identified resistance mutations.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-40974-8","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T10:02:39Z","timestamp":1692957759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Propensity of selecting mutant parasites for the antimalarial drug cabamiquine"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5129-8180","authenticated-orcid":false,"given":"Eva","family":"Stadler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1537-9087","authenticated-orcid":false,"given":"Mohamed","family":"Maiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Thathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-2962","authenticated-orcid":false,"given":"Claudia","family":"Demarta-Gatsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7739-4437","authenticated-orcid":false,"given":"Antoine","family":"Dara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanta","family":"Sogore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4673-3114","authenticated-orcid":false,"given":"Josefine","family":"Striepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Oeuvray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0062-2283","authenticated-orcid":false,"given":"Abdoulaye A.","family":"Djimd\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-0915","authenticated-orcid":false,"given":"Marcus C. S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Demb\u00e9l\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-8938","authenticated-orcid":false,"given":"David A.","family":"Fidock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-1551","authenticated-orcid":false,"given":"David S.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-8919","authenticated-orcid":false,"given":"Thomas","family":"Spangenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"40974_CR1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm.4381","volume":"23","author":"B Blasco","year":"2017","unstructured":"Blasco, B., Leroy, D. & Fidock, D. A. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat. Med. 23, 917\u2013928 (2017).","journal-title":"Nat. Med."},{"key":"40974_CR2","unstructured":"World Health Organization. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. https:\/\/www.who.int\/docs\/default-source\/documents\/publications\/gmp\/who-cds-gmp-2019-17-eng.pdf?ua=1 (2018)."},{"key":"40974_CR3","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm, R. W. et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect. Dis. 19, 952\u2013961 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"40974_CR4","volume":"11","author":"XC Ding","year":"2012","unstructured":"Ding, X. C., Ubben, D. & Wells, T. N. A framework for assessing the risk of resistance for anti-malarials in development. Malar. J. 11, 292 (2012).","journal-title":"Malar. J."},{"key":"40974_CR5","doi-asserted-by":"crossref","first-page":"e21914","DOI":"10.1371\/journal.pone.0021914","volume":"6","author":"JS McCarthy","year":"2011","unstructured":"McCarthy, J. S. et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS ONE 6, e21914 (2011).","journal-title":"PLoS ONE"},{"key":"40974_CR6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2012.02.021","volume":"148","author":"DE Goldberg","year":"2012","unstructured":"Goldberg, D. E., Siliciano, R. F. & Jacobs, W. R. Jr Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 148, 1271\u20131283 (2012).","journal-title":"Cell"},{"key":"40974_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","volume":"522","author":"B Baraga\u00f1a","year":"2015","unstructured":"Baraga\u00f1a, B. et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 522, 315\u2013320 (2015).","journal-title":"Nature"},{"key":"40974_CR8","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1021\/acs.jmedchem.0c01746","volume":"64","author":"A Fan","year":"2021","unstructured":"Fan, A. & Sharp, P. P. Inhibitors of eukaryotic translational machinery as therapeutic agents. J. Med. Chem. 64, 2436\u20132465 (2021).","journal-title":"J. Med. Chem."},{"key":"40974_CR9","doi-asserted-by":"crossref","first-page":"e02181","DOI":"10.1128\/AAC.02181-19","volume":"64","author":"M Rottmann","year":"2020","unstructured":"Rottmann, M. et al. Preclinical antimalarial combination study of M5717, a Plasmodium falciparum elongation Factor 2 inhibitor, and pyronaridine, a Hemozoin Formation inhibitor. Antimicrob. Agents Chemother. 64, e02181 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40974_CR10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"JS McCarthy","year":"2021","unstructured":"McCarthy, J. S. et al. Safety, pharmacokinetics, and antimalarial activity of the novel eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. Lancet Infect. Dis. 21, 1713\u20131724 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"40974_CR11","doi-asserted-by":"crossref","first-page":"e30949","DOI":"10.1371\/journal.pone.0030949","volume":"7","author":"LM Sanz","year":"2012","unstructured":"Sanz, L. M. et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS ONE 7, e30949 (2012).","journal-title":"PLoS ONE"},{"key":"40974_CR12","doi-asserted-by":"crossref","first-page":"15727","DOI":"10.1021\/acs.jmedchem.1c01014","volume":"64","author":"CJ Zerio","year":"2021","unstructured":"Zerio, C. J. et al. Discovery of an eIF4A inhibitor with a novel mechanism of action. J. Med. Chem. 64, 15727\u201315746 (2021).","journal-title":"J. Med. Chem."},{"key":"40974_CR13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","volume":"18","author":"A Llanos-Cuentas","year":"2018","unstructured":"Llanos-Cuentas, A. et al. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. Lancet Infect. Dis. 18, 874\u2013883 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"40974_CR14","doi-asserted-by":"crossref","first-page":"296ra111","DOI":"10.1126\/scitranslmed.aaa6645","volume":"7","author":"MA Phillips","year":"2015","unstructured":"Phillips, M. A. et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci. Transl. Med. 7, 296ra111 (2015).","journal-title":"Sci. Transl. Med."},{"key":"40974_CR15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/acsinfecdis.8b00211","volume":"5","author":"J White","year":"2019","unstructured":"White, J. et al. Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the clinical candidate DSM265. ACS Infect. Dis. 5, 90\u2013101 (2019).","journal-title":"ACS Infect. Dis."},{"key":"40974_CR16","doi-asserted-by":"crossref","first-page":"eaav1636","DOI":"10.1126\/scitranslmed.aav1636","volume":"11","author":"REK Mandt","year":"2019","unstructured":"Mandt, R. E. K. et al. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model. Sci. Transl. Med. 11, eaav1636 (2019).","journal-title":"Sci. Transl. Med."},{"key":"40974_CR17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","volume":"17","author":"JS McCarthy","year":"2017","unstructured":"McCarthy, J. S. et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study. Lancet Infect. Dis. 17, 626\u2013635 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"40974_CR18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jtbi.2009.07.038","volume":"261","author":"HY Lee","year":"2009","unstructured":"Lee, H. Y. et al. Modeling sequence evolution in acute HIV-1 infection. J. Theor. Biol. 261, 341\u2013360 (2009).","journal-title":"J. Theor. Biol."},{"key":"40974_CR19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/AAC.00903-07","volume":"52","author":"K Stepniewska","year":"2008","unstructured":"Stepniewska, K. & White, N. J. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52, 1589\u20131596 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40974_CR20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.pt.2020.07.004","volume":"36","author":"DS Khoury","year":"2020","unstructured":"Khoury, D. S. et al. The interdisciplinary approaches to malaria consortium. Artemisinin resistance and the unique selection pressure of a short-acting antimalarial. Trends Parasitol. 36, 884\u2013887 (2020).","journal-title":"Trends Parasitol."},{"key":"40974_CR21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1098\/rstb.2001.1036","volume":"357","author":"IM Hastings","year":"2002","unstructured":"Hastings, I. M., Watkins, W. M. & White, N. J. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 505\u2013519 (2002).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"40974_CR22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nature05685","volume":"446","author":"R Chait","year":"2007","unstructured":"Chait, R., Craney, A. & Kishony, R. Antibiotic interactions that select against resistance. Nature 446, 668\u2013671 (2007).","journal-title":"Nature"},{"key":"40974_CR23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.pt.2020.08.008","volume":"36","author":"AC Brown","year":"2020","unstructured":"Brown, A. C. & Guler, J. L. From circulation to cultivation: Plasmodium in vivo versus in vitro. Trends Parasitol. 36, 914\u2013926 (2020).","journal-title":"Trends Parasitol."},{"key":"40974_CR24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjh.14886","volume":"179","author":"MM Goheen","year":"2017","unstructured":"Goheen, M. M., Campino, S. & Cerami, C. The role of the red blood cell in host defence against falciparum malaria: an expanding repertoire of evolutionary alterations. Br. J. Haematol. 179, 543\u2013556 (2017).","journal-title":"Br. J. Haematol."},{"key":"40974_CR25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41586-021-04288-3","volume":"602","author":"G Band","year":"2022","unstructured":"Band, G. et al. Malaria protection due to sickle haemoglobin depends on parasite genotype. Nature 602, 106\u2013111 (2022).","journal-title":"Nature"},{"key":"40974_CR26","doi-asserted-by":"crossref","first-page":"e69808","DOI":"10.7554\/eLife.69808","volume":"10","author":"ER Ebel","year":"2021","unstructured":"Ebel, E. R., Kuypers, F. A., Lin, C., Petrov, D. A. & Egan, E. S. Common host variation drives malaria parasite fitness in healthy human red cells. eLife 10, e69808 (2021).","journal-title":"eLife"},{"key":"40974_CR27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/emph\/eoy016","volume":"2018","author":"S Huijben","year":"2018","unstructured":"Huijben, S., Chan, B. H. K., Nelson, W. A. & Read, A. F. The impact of within-host ecology on the fitness of a drug-resistant parasite. Evol. Med. Public Health 2018, 127\u2013137 (2018).","journal-title":"Evol. Med. Public Health"},{"key":"40974_CR28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/jtbi.1997.0438","volume":"194","author":"DJ Austin","year":"1998","unstructured":"Austin, D. J., White, N. J. & Anderson, R. M. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J. Theor. Biol. 194, 313\u2013339 (1998).","journal-title":"J. Theor. Biol."},{"key":"40974_CR29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0160-9327(84)90080-2","volume":"8","author":"WH Wernsdorfer","year":"1984","unstructured":"Wernsdorfer, W. H. Drug resistant malaria. Endeavour 8, 166\u2013171 (1984).","journal-title":"Endeavour"},{"key":"40974_CR30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02440-6","volume":"7","author":"L Dembele","year":"2017","unstructured":"Dembele, L. et al. The plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci. Rep. 7, 2325 (2017).","journal-title":"Sci. Rep."},{"key":"40974_CR31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1126\/science.781840","volume":"193","author":"W Trager","year":"1976","unstructured":"Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673\u2013675 (1976).","journal-title":"Science"},{"key":"40974_CR32","doi-asserted-by":"crossref","unstructured":"Doolan, D. L. Malaria Methods and Protocols (Springer Science+Business Media, 2002).","DOI":"10.1385\/1592592716"},{"key":"40974_CR33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2307\/3280287","volume":"65","author":"C Lambros","year":"1979","unstructured":"Lambros, C. & Vanderberg, J. P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65, 418\u2013420 (1979).","journal-title":"J. Parasitol."},{"key":"40974_CR34","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1128\/AAC.00519-09","volume":"53","author":"MB Jim\u00e9nez-D\u00edaz","year":"2009","unstructured":"Jim\u00e9nez-D\u00edaz, M. B. et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob. Agents Chemother. 53, 4533\u20134536 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40974_CR35","doi-asserted-by":"crossref","first-page":"e02181","DOI":"10.1128\/AAC.02181-19","volume":"64","author":"M Rottmann","year":"2020","unstructured":"Rottmann, M. et al. Preclinical antimalarial combination study of M5717, a Plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor. Antimicrob. Agents Chemother. 64, e02181\u201319 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40974_CR36","doi-asserted-by":"crossref","first-page":"e2252","DOI":"10.1371\/journal.pone.0002252","volume":"3","author":"I Angulo-Barturen","year":"2008","unstructured":"Angulo-Barturen, I. et al. A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS ONE 3, e2252 (2008).","journal-title":"PLoS ONE"},{"key":"40974_CR37","doi-asserted-by":"crossref","first-page":"19455","DOI":"10.1073\/pnas.1919672117","volume":"117","author":"HK Alexander","year":"2020","unstructured":"Alexander, H. K. & MacLean, R. C. Stochastic bacterial population dynamics restrict the establishment of antibiotic resistance from single cells. Proc. Natl Acad. Sci. USA 117, 19455\u201319464 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"40974_CR38","doi-asserted-by":"crossref","first-page":"e1003293","DOI":"10.1371\/journal.pgen.1003293","volume":"9","author":"SE Bopp","year":"2013","unstructured":"Bopp, S. E. et al. Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLOS Genet 9, e1003293 (2013).","journal-title":"PLOS Genet"},{"key":"40974_CR39","doi-asserted-by":"crossref","first-page":"e1004812","DOI":"10.1371\/journal.pgen.1004812","volume":"10","author":"A Claessens","year":"2014","unstructured":"Claessens, A. et al. Generation of antigenic diversity in Plasmodium falciparum by structured rearrangement of Var genes during mitosis. PLOS Genet 10, e1004812 (2014).","journal-title":"PLOS Genet"},{"key":"40974_CR40","first-page":"1889","volume":"45","author":"WL Hamilton","year":"2017","unstructured":"Hamilton, W. L. et al. Extreme mutation bias and high AT content in Plasmodium falciparum. Nucleic Acids Res. 45, 1889\u20131901 (2017).","journal-title":"Nucleic Acids Res."},{"key":"40974_CR41","doi-asserted-by":"crossref","first-page":"e0154166","DOI":"10.1371\/journal.pone.0154166","volume":"11","author":"AH Lee","year":"2016","unstructured":"Lee, A. H. & Fidock, D. A. Evidence of a mild mutator phenotype in Cambodian Plasmodium falciparum malaria parasites. PLoS ONE 11, e0154166 (2016).","journal-title":"PLoS ONE"},{"key":"40974_CR42","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1038\/s41596-021-00628-9","volume":"16","author":"Z Du","year":"2021","unstructured":"Du, Z. et al. The trRosetta server for fast and accurate protein structure prediction. Nat. Protoc. 16, 5634\u20135651 (2021).","journal-title":"Nat. Protoc."},{"key":"40974_CR43","unstructured":"trRosetta. http:\/\/yanglab.nankai.edu.cn\/trRosetta\/ (2022)."},{"key":"40974_CR44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"40974_CR45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221\u2013234 (2013).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"40974_CR46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/ci800324m","volume":"49","author":"TA Halgren","year":"2009","unstructured":"Halgren, T. A. Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model. 49, 377\u2013389 (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"40974_CR47","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750\u20131759 (2004).","journal-title":"J. Med. Chem."},{"key":"40974_CR48","doi-asserted-by":"publisher","unstructured":"Stadler, E. estadler\/cabamiquine: Cabamiquine resistance estimates & math. modelling (v1.0). Zenodo. https:\/\/doi.org\/10.5281\/zenodo.8111676 (2023).","DOI":"10.5281\/zenodo.8111676"}],"updated-by":[{"DOI":"10.1038\/s41467-023-41287-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40974-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T09:18:22Z","timestamp":1700126302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40974-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40974"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-40974-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-023-41287-6","URL":"https:\/\/doi.org\/10.1038\/s41467-023-41287-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.F. is employed by Merck Healthcare, Darmstadt, Germany. C.D.G., C.O., and T.S. are employed by Ares Trading S.A., Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. All other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5205"}}